The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Wonder how the Phase 2 Covid trial start date is getting on…Imminent hopefully
Denny, the high price was more to do with the ADR ratio change from 5:1 to 2:1 causing confusion over the pond IMO.
Although I do agree slightly, there were some yanks and there still are some yanks mixing up TLSA and TSLA but I’m not sure it was enough to really move the SP.
I believe the herd mentality also came into play a year ago which resulted in a shortage of stock for MM’s, thus driving the price up.
Hopefully we will see that herd mentality again in the future but excitement is needed around the stock which is lacking at the moment.
Roker, er disagree. Look at the valuations of similar companies. ITEOS has been flirting around the $1billion MCAP in recent months during a period where BioPharma stocks are pretty flat.
PRVB were comfortably over a $1.2billion MCAP whilst in Phase 3 trials.
If Foralumab is as good as what they think, maybe expect a JV or licensing deal similar to ITOS but I don’t think he’ll sell it outright for $1 billion.
If he does, happy days, I’m quids in but I think he’s built a team around him with a proven track record of delivery therapeutics and some of those guys will want to see it through along with the kudos that brings.
204p would be a cheeky bid. I doubt GC would even entertain a lowball offer like that but it would be a case of ‘the first shot across the bow’.
This could then but other interested parties to the table, hopefully resulting in a bidding war.
He won’t sell for less than $1billion IMO
No patent has been issued yet.
It depends on people’s interpretation of ‘the company believes the technology could also be applicable for use with other FDA approved mAbs and drugs’.
Ultimately it will come down to the patent attorneys interpretation and how they summarise it, if/when a patent is issued.
‘The Company believes the technology could also be applicable for use with other FDA approved mAbs and drugs’.
To me, the patent application has more substance for the delivery of anti IL6 MAB’s only or TZLS-501 in particular.
So no, is the answer to your question.
Inhalers have been around for many years.
New York/London -- April 9, 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for inflammatory and autoimmune diseases, announced today that it has developed investigational new technology to treat COVID-19 infections, which consists of direct delivery of anti-IL-6 receptor (anti-IL-6R) monoclonal antibodies (mAbs) into the lungs using a handheld inhaler or nebulizer. Development of this novel technology is a step forward toward expediting development of TZLS-501, a fully-human anti-interleukin-6 receptor (anti-IL6R) monoclonal antibody (mAb) for treatment of patients infected with COVID-19 (SARS-CoV-2) coronavirus. The Company believes the technology could also be applicable for use with other FDA approved mAbs and drugs. The Company has submitted a provisional patent application for the delivery technology.
Whoever loads up heavily at these levels and holds patiently will get the opportunity to retire in France!
Might see an RNS drop tomorrow morning.
It was mentioned that the TLSA price action on Friday could have been linked to Aridis pharma which surged to +30% then finished -12%, a strange 40% swing.
TLSA finished strongly, +14% on the day and +3.38% after hours.
Unlikely it was the ARDS effect, hopefully a leak and we got some good news to get the SP moving upwards again.
There’s some big boys there, surely some of those have been licking their lips at these depressed levels and taken the opportunity to increase their position.
The figures are recent, 1st June 21.
It will be interesting to see if AJ Bell, Charles Stanley, Eurizon and Morgan Stanley continue to load up, all have done recently.
Hightower and Empery are still there.
25% total between hedge funds and institutional investors, not massive.
Need another institutional investor on board or one of the others to load up to really get things going.
On top of some welcome news, of course.
https://simplywall.st/stocks/gb/pharmaceuticals-biotech/lse-tils/tiziana-life-sciences-shares
The government want cheap drugs.
Guess who can provide the most cost effective way of administering a MAB…TILS
TILS isn’t a start up. The company has been established for quite a while now and done the hard yards. The $57m raise surpassed any financing the company had done previously and all the pointers are towards a company on the verge of achieving big things.
Managed to dig out £1000 for a Monday morning top up at 65.8p. Hopefully these levels will be laughable in future months. Interesting week ahead. GLA.
Fair play to the guy for being honest.
I do believe these posts have an impact and help sow the seed of doubt in people’s minds, thus they sell and it affects the SP.
There are also some very wealthy people who operate on these boards, known multimillionaires and they can also be influenced positively or negatively like the rest of us by gauging sentiment.
There’s been a lot of negativity on this BB over the last 6 months which is unlikely to entice future investors and I agree with a point made the other day that investors here have inadvertently harmed their investment with the ongoing negative narrative.
Blue, yes plenty of potential for a quick move here.
Not all Covid stocks have been hit hard, SNG is showing strength.
News flow has been quiet for TILS in 2021 but I expect things to start ramping up any time.
Keep the faith Busy, I’m 32k down here now but feeling pretty confident it will turn for us.
Busy, I would be amazed if the start of the Phase2 Covid trial didn’t have a positive effect on the SP.
It’s a major step towards potentially even bigger news towards the year end, proof of concept.
I can’t remember who but somebody here posted an interesting chart a couple of months ago showing the increase in MCAP when a company enters into Phase2 trials.